Exchange: NASDAQ·Updated 07:30 PM EST
SABS logo

SABS SAB Biotherapeutics Inc

$2.81
$0.10
(3.44%)
Today
Closed $2.81
$0.00
(0.00%)
After Hours
Reported EarningsNov 5
Mkt Cap$253.15M
Vol874,567.00

About SABS

SAB Biotherapeutics, Inc. is a clinical-stage, biopharmaceutical company, which engages in advancing a new class of immunotherapies leveraging fully-human polyclonal antibodies. It produces human polyclonal immunotherapies and its versatile DiversitAb platform is applicable for unmet needs in human diseases. The company was founded by Eddie J. Sullivan and Christine E. Hamilton in July 2014 and is headquartered in Miami Beach, FL.
49

Neutral Sentiment

How do you feel about SABS?

JTebow_CWS
$SABS If you are looking for historical, non-genetically modified use of native bovine antibodies/colostrum for passive immunity in human gut infections, PubMed indexes clinical success tracking back to 1987 for rotavirus, but the 2009 paper is the landmark study for engineering cows to produce targetable human therapeutic antibodies)
9
Aawilliam2003
$SABS someone needed to get out in a hurry. some hedge funds could be in trouble in this market
2

Advertisement|Remove ads.